Biotage is a Global Impact Tech Company committed to solving society’s problems. We offer workflow solutions and products to customers in drug discovery and development and diagnostics, analytical testing and water and environmental testing.
Biotage is contributing to sustainable science with the goal to make the world healthier, greener and cleaner – HumanKind Unlimited.
Our customers span a broad range of market segments including pharmaceutical, biotech, diagnostic, contract research and contract manufacturers as well as clinical, forensic and academic laboratories in addition to organizations focused on food safety, clean water and environmental sustainability.
Biotage is headquartered in Uppsala in Sweden and employs 497 people worldwide. The Group had sales of 1,232 MSEK in 2021 and our products are sold in more than 80 countries. Biotage’s share (BIOT) is listed in the Large Cap segment on the NASDAQ Stockholm.
1999
Served areaWorldwide
Headcount497
HeadquartersVimpelgatan 5, 75318 Uppsala – Sweden
Line item in (sek) | 01.01.2020 | 01.01.2021 | 01.01.2022 | 01.01.2023 |
---|---|---|---|---|
Assets | N/A | 1,434,000,000.00 | 1,992,000,000.00 | 2,339,000,000.00 |
Noncurrent Assets | N/A | 683,000,000.00 | 1,218,000,000.00 | 1,308,000,000.00 |
Property Plant And Equipment | N/A | 53,000,000.00 | 76,000,000.00 | 96,000,000.00 |
Goodwill | N/A | 290,000,000.00 | 741,000,000.00 | 794,000,000.00 |
Intangible Assets Other Than Goodwill | N/A | 129,000,000.00 | 185,000,000.00 | 172,000,000.00 |
Deferred Tax Assets | N/A | 26,000,000.00 | 22,000,000.00 | 23,000,000.00 |
Other Noncurrent Financial Assets | N/A | 12,000,000.00 | 14,000,000.00 | 21,000,000.00 |
Current Assets | N/A | 752,000,000.00 | 774,000,000.00 | 1,031,000,000.00 |
Inventories | N/A | 160,000,000.00 | 237,000,000.00 | 305,000,000.00 |
Trade And Other Current Receivables | N/A | 194,000,000.00 | 180,000,000.00 | 223,000,000.00 |
Other Current Nonfinancial Assets | N/A | 26,000,000.00 | 46,000,000.00 | 62,000,000.00 |
Cash and cash equivalents | 186,000,000.00 | 371,000,000.00 | 311,000,000.00 | 441,000,000.00 |
Equity And Liabilities | N/A | N/A | 1,992,000,000.00 | 2,339,000,000.00 |
Equity | 876,000,000.00 | 990,000,000.00 | 1,371,000,000.00 | 1,637,000,000.00 |
Issued Capital | N/A | 91,000,000.00 | 92,000,000.00 | 93,000,000.00 |
Retained Earnings | N/A | 956,000,000.00 | 1,063,000,000.00 | 1,229,000,000.00 |
Liabilities | N/A | 1,434,000,000.00 | 1,992,000,000.00 | N/A |
Noncurrent Liabilities | N/A | 227,000,000.00 | 307,000,000.00 | 285,000,000.00 |
Other Longterm Provisions | N/A | 3,000,000.00 | 10,000,000.00 | 5,000,000.00 |
Deferred Tax Liabilities | N/A | 33,000,000.00 | 73,000,000.00 | 71,000,000.00 |
Other Noncurrent Financial Liabilities | N/A | 51,000,000.00 | 45,000,000.00 | 17,000,000.00 |
Longterm Borrowings | N/A | 110,000,000.00 | 150,000,000.00 | 150,000,000.00 |
Current Liabilities | N/A | 217,000,000.00 | 313,000,000.00 | 417,000,000.00 |
Other Shortterm Provisions | N/A | 8,000,000.00 | 3,000,000.00 | 3,000,000.00 |
Trade And Other Current Payables | N/A | 51,000,000.00 | 56,000,000.00 | 57,000,000.00 |
Other Current Financial Liabilities | N/A | 2,000,000.00 | 2,000,000.00 | 8,000,000.00 |
Other Current Nonfinancial Liabilities | N/A | 135,000,000.00 | 229,000,000.00 | 325,000,000.00 |
Line item in (sek) | 01.01.2020/ 01.01.2021 |
01.01.2021/ 01.01.2022 |
01.01.2022/ 01.01.2023 |
---|---|---|---|
Revenue | 1,092,000,000.00 | 1,232,000,000.00 | 1,566,000,000.00 |
Other Income | 21,000,000.00 | 17,000,000.00 | 37,000,000.00 |
Profit Loss From Operating Activities | 206,000,000.00 | 271,000,000.00 | 327,000,000.00 |
Finance Income | 26,000,000.00 | 10,000,000.00 | 35,000,000.00 |
Finance Costs | 9,000,000.00 | 12,000,000.00 | 14,000,000.00 |
Profit Loss Before Tax | 223,000,000.00 | 269,000,000.00 | 348,000,000.00 |
Income Tax Expense Continuing Operations | 47,000,000.00 | 64,000,000.00 | 80,000,000.00 |
Profit (loss) | 175,000,000.00 | 205,000,000.00 | 268,000,000.00 |
Profit Loss Attributable To Owners Of Parent | 175,000,000.00 | 205,000,000.00 | 268,000,000.00 |
Line item in (sek) | 01.01.2020 | 01.01.2021 | 01.01.2022 | 01.01.2023 |
---|---|---|---|---|
Profit (loss) | N/A | 175,000,000.00 | 205,000,000.00 | 268,000,000.00 |
Adjustments For Reconcile Profit Loss | N/A | 63,000,000.00 | -78,000,000.00 | -84,000,000.00 |
Adjustments For Decrease Increase In Inventories | N/A | -5,000,000.00 | -54,000,000.00 | -45,000,000.00 |
Adjustments For Unrealised Foreign Exchange Losses Gains | N/A | 6,000,000.00 | 4,000,000.00 | 4,000,000.00 |
Adjustments For Fair Value Gains Losses | N/A | -25,000,000.00 | -9,000,000.00 | -28,000,000.00 |
Other Adjustments For Noncash Items | N/A | 8,000,000.00 | 9,000,000.00 | 7,000,000.00 |
Adjustments For Reconcile Profit Loss | N/A | 63,000,000.00 | -78,000,000.00 | -84,000,000.00 |
Interest Paid Classified As Operating Activities | N/A | 3,000,000.00 | 3,000,000.00 | 5,000,000.00 |
Interest Received Classified As Operating Activities | N/A | 0.00 | 0.00 | 2,000,000.00 |
Cash Flows From Used In Operating Activities | N/A | 279,000,000.00 | 353,000,000.00 | 341,000,000.00 |
Cash Flows Used In Obtaining Control Of Subsidiaries Or Other Businesses Classified As Investing Activities | N/A | 0.00 | 282,000,000.00 | 12,000,000.00 |
Other Cash Payments To Acquire Equity Or Debt Instruments Of Other Entities Classified As Investing Activities | N/A | 1,000,000.00 | 2,000,000.00 | 2,000,000.00 |
Purchase Of Property Plant And Equipment Classified As Investing Activities | N/A | 18,000,000.00 | 23,000,000.00 | 35,000,000.00 |
Purchase Of Intangible Assets Classified As Investing Activities | N/A | 43,000,000.00 | 33,000,000.00 | 35,000,000.00 |
Proceeds From Other Longterm Assets Classified As Investing Activities | N/A | 0.00 | 0.00 | 0.00 |
Cash Flows From Used In Investing Activities | N/A | -62,000,000.00 | -341,000,000.00 | -84,000,000.00 |
Proceeds From Borrowings Classified As Financing Activities | N/A | 0.00 | 150,000,000.00 | 150,000,000.00 |
Repayments Of Borrowings Classified As Financing Activities | N/A | N/A | 134,000,000.00 | 180,000,000.00 |
Cash Flows From Used In Financing Activities | N/A | -23,000,000.00 | -82,000,000.00 | -133,000,000.00 |
Increase (decrease) in cash and cash equivalents before effect of exchange rate changes | N/A | 195,000,000.00 | -69,000,000.00 | 124,000,000.00 |
Effect Of Exchange Rate Changes On Cash And Cash Equivalents | N/A | -10,000,000.00 | 9,000,000.00 | 7,000,000.00 |
Cash and cash equivalents | 186,000,000.00 | 371,000,000.00 | 311,000,000.00 | 441,000,000.00 |
Please note that some sums might not add up.
Date | Trading entity / Person | Association | Trade type | Volume |
---|---|---|---|---|
18.07.23 | Scott Carr | Other | Other | SEK 0.00 |
28.04.23 | Gustaf Peter Reinhold von Ehrenheim | Other | Buy | SEK 2,015,520.00 |
20.05.21 | Anders Wikström | Other | Sell | SEK 265,500.00 |
09.11.20 | Jon-Sverre Schanche | Other | Buy | SEK 145,000.00 |
05.10.20 | Thomas Eklund | Other | Sell | SEK 2,608,500.00 |
03.09.20 | torben jörgensen | Other | Sell | SEK 76,590.00 |
06.08.20 | Lars Ivar Bäckman | Other | Sell | SEK 1,662,038.00 |
22.05.20 | Esbjörn Jonas Love Amcoff | Other | Sell | SEK 361,260.00 |
11.05.20 | Karolina Lawitz | Other | Sell | SEK 317,500.00 |
07.05.20 | Thomas Eklund | Other | Sell | SEK 2,651,327.80 |
SE0000454746
LEI529900SR87NBUKX74L58
SectorHealth Care Equipment & Services
IndustryKeep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.